


Amendments to the Claims:

1. (Currently amended) A compound of the formula:



and the or a pharmaceutically acceptable salts, ~~hydrates, and prodrugs~~ thereof, wherein;

- a) R¹ is represented by ~~halogen~~, (C₁-C₂)alkyl, substituted with one or more halogens, or (C₁-C₂)alkoxy, substituted with one or more halogens,
- b) R² is represented by hydrogen or halogen,
- c) X¹ and X² are each independently represented by
 - i) (C₁-C₁₂)alkyl, optionally substituted,
 - ii) (C₂-C₁₂)alkenyl, optionally substituted,
 - iii) (C₂-C₁₂)alkynyl, optionally substituted,
 - iv) (C₃-C₁₀)cycloalkyl, optionally substituted,
 - v) (C₃-C₁₀)cycloalkyl(C₁-C₆)alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
 - vi) (C₆-C₁₀)aryl, optionally substituted,
 - vii) (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
 - viii) -(CH₂)q-CH₂-ZH, in which Z is S or O and q is an integer from 1-11,
 - ix) -(CH₂)n-Y-(CH₂)p-CH₃, in which Y is O or S, n is an integer from 1 to 4, and p is an integer from 1 to 4,
 - x) -[CH₂]m-C(O)R³, in which m is an integer selected from 1 to 8 and R³ is represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or (C₆-

- C₁₀)aryl(C₁-C₆)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
- xi) -[CH₂]_m-C(O)-O-R⁴, in which m is as defined above and R⁴ is represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which the alkyl and aryl moieties may be optionally substituted,
 - xii) -[CH₂]_m-C(O)-NR⁵R⁶ in which m is as described above, and R⁵ and R⁶ are each independently represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
 - i) heteroaryl, optionally substituted,
 - ii) heteroaryl(C₁-C₆)alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted,
 - iii) heterocyclic, optionally substituted, or,
 - iv) heterocyclic(C₁-C₆)alkyl, in which the alkyl and heterocyclic moieties may each be optionally substituted.
2. (Original) A compound according to claim 1 in which R¹ is represented by trifluomethyl.
 3. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] 4** ~~or 2~~ in which said trifluoromethyl is located at the 4-position of the pyridine ring.
 4. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] 1-3** ~~2~~ in which R² is hydrogen.
 5. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] [[1-4]]2** in which X¹ is (C₁-C_{[[12]]₁₂})alkyl and X_{[[2]]² is (C_{[[6]]₆}-C_{[[10]]₁₀})aryl(C_{[[1]]₁}-C_{[[6]]₆})alkyl.}
 6. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] [[1-5]]2** in which X¹ and X² are each (C₁-C₁₂)alkyl

7. (Currently amended) A compound according to ~~anyone of claim~~ ~~[[s]]~~ ~~[[1-6]]~~ ~~2~~ in which X^1 is (C_1-C_{12}) alkyl and $X^{[2]}$ is $(C^{[[3]]}_3-C^{[[10]]}_{10})$ cycloalkyl($C^{[[1]]}_1-C^{[[6]]}_6$)alkyl.

8. (Original) A compound according to claim 1 selected from the group consisting of
 (R)-(+)- 6-[Methyl-(1-Phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 (R)-(+)-2-Chloro-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,
 6-[methyl-(1-(4-fluorophenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 6-[methyl-(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 6-[butyl(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,
 6-dipropylamino-4-trifluoromethyl-nicotinonitrile,
 2-chloro-6-dimethylamino-4-trifluoromethyl-nicotinonitrile,
 6-(hexyl-octyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-(sec-butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-[butyl-(2-hydroxy-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
 6-(butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-(benzyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-(cyclohexyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-(cyclopropylmethyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,
 6-(sec-butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile,
 6-Dipropylamino-2-chloro-4-trifluoromethyl-nicotinonitrile,
 6-(propyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile, and,
 6-(Butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile.


9. (Currently amended) Use of a compound according to ~~anyone of Claim~~ ~~[[s]]~~ ~~1~~ ~~[[8]]~~ as a medicine.

10. (Currently amended) ~~Use of a compound according to anyone of Claims 1-8 in the manufacture of a medicament~~ A method for inhibiting activation of the androgen receptor~~[[.]]~~ , comprising, administering a compound according to Claim 1 to a patient in need thereof.

11. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ in admixture with 1, or more, pharmaceutically acceptable excipients.
12. (Currently amended) A topical pharmaceutical formulation comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.
13. (Currently amended) ~~An article of manufacture~~ A kit comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.
14. (Currently amended) ~~Use of a compound according to any one of claims 1-8 in the manufacture of a medicament for alleviating~~ A method of treating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia comprising the administration of a compound according to claim 1.

Date: 5/18/06

Respectfully submitted,

By 
J. Michael Dixon
Reg. No. 32,410
Tel.: (734) 622-1705
Fax: (734) 622-1553